Fusion Winter 2012

https://kent-islandora.s3.us-east-2.amazonaws.com/fusion/16/thumbnail.jp

UV emitting glass: A promising strategy for biofilm inhibition on transparent surfaces

Marine biofouling causes serious environmental problems and has adverse impacts on the maritime industry. Biofouling on windows and optical equipment reduces surface transparency, limiting their application for on-site monitoring or continuous measurement. This work illustrates that UV emitting glasses (UEGs) can prevent the establishment and growth of biofilm on the illuminated surfaces. Specifically, this paper describes how UEGs are enabled by innovatively modifying the surfaces of the glass with light scattering particles. Modification of glass surface with silica nanoparticles at a concentration 26.5 μg/cm2 resulted in over ten-fold increase in UV irradiance, while maintaining satisfactory visible and IR transparency metrics of over 99 %. The UEG reduced visible biological growth by 98 % and resulted in a decrease of 1.79 log in detected colony forming units when compared to the control during a 20 day submersion at Port Canaveral, Florida, United States. These findings serve as strong evidence that UV emitting glass should be explored as a promising approach for biofilm inhibition on transparent surfaces

Fusion Spring 2013

https://kent-islandora.s3.us-east-2.amazonaws.com/fusion/19/thumbnail.jp

The Burr November 2012

https://kent-islandora.s3.us-east-2.amazonaws.com/theburr/54/thumbnail.jp

Time to Peak Glucose and Peak C-Peptide During the Progression to Type 1 Diabetes in the Diabetes Prevention Trial and TrialNet Cohorts

OBJECTIVE To assess the progression of type 1 diabetes using time to peak glucose or C-peptide during oral glucose tolerance tests (OGTTs) in autoantibody-positive relatives of people with type 1 diabetes. RESEARCH DESIGN AND METHODS We examined 2-h OGTTs of participants in the Diabetes Prevention Trial Type 1 (DPT-1) and TrialNet Pathway to Prevention (PTP) studies. We included 706 DPT-1 participants (mean ± SD age, 13.84 ± 9.53 years; BMI Z-score, 0.33 ± 1.07; 56.1% male) and 3,720 PTP participants (age, 16.01 ± 12.33 years; BMI Z-score, 0.66 ± 1.3; 49.7% male). Log-rank testing and Cox regression analyses with adjustments (age, sex, race, BMI Z-score, HOMA-insulin resistance, and peak glucose/C-peptide levels, respectively) were performed. RESULTS In each of DPT-1 and PTP, higher 5-year diabetes progression risk was seen in those with time to peak glucose >30 min and time to peak C-peptide >60 min (P < 0.001 for all groups), before and after adjustments. In models examining strength of association with diabetes development, associations were greater for time to peak C-peptide versus peak C-peptide value (DPT-1: χ2 = 25.76 vs. χ2 = 8.62; PTP: χ2 = 149.19 vs. χ2 = 79.98; all P < 0.001). Changes in the percentage of individuals with delayed glucose and/or C-peptide peaks were noted over time. CONCLUSIONS In two independent at-risk populations, we show that those with delayed OGTT peak times for glucose or C-peptide are at higher risk of diabetes development within 5 years, independent of peak levels. Moreover, time to peak C-peptide appears more predictive than the peak level, suggesting its potential use as a specific biomarker for diabetes progression